ICCM
IceCure Medical Ltd
Set alert
- YTD
- -95.25%
- 1 year
- -95.92%
- Open
- 0.94
- Prev close
- 0.9284
- Mkt cap
- 4.04M
- Vol
- 50.26K
- Avg vol
- 145.59K
- EPS
- -6.84
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.8201
- High
- 0.951
- Forward P/E
- -4.48
- Beta
- 2.63
- Short ratio
- 0.46
- Inst. own
- 0.40%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 20, 2024
- 50-d avg
- 0.74766
- 200-d avg
- 0.852735
- 1y target
- 3.37
Key statistics
- Market cap
- 62.16M
- Enterprise value
- 28.55M
- Trailing P/E
- 0.00
- Forward P/E
- -4.48
- PEG ratio
- 0.00
- Price / sales
- 18.63
- Price / book
- 4.21
- EPS (TTM)
- -0.28
- Beta
- 2.63
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 3.34M
- Revenue growth
- 7.90%
- Free cash flow
- -6.62M
- Total cash
- 10.46M
- Total debt
- 520.00K
- Return on equity
- -94.22%
- Shares outstanding
- 55.50M
- Short % of float
- 0.98%
- 50-day average
- 0.74766
- 200-day average
- 0.852735
Analyst view
Consensus: none
- Target (low)
- 2.50
- Target (mean)
- 3.37
- Target (high)
- 4.60
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 20, 2024
Expected Aug 20, 2024. Consensus EPS estimate -0.07.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 26, 2024 | Sep 1, 2024 | -0.07 | -0.08 | -0.01 | -14.29% |
| Aug 20, 2024 | Jun 1, 2024 | -0.07 | — | — | — |
| Aug 20, 2024 | Jun 1, 2024 | -0.07 | -0.06 | +0.01 | +14.29% |
| May 28, 2024 | Mar 1, 2024 | -0.08 | — | — | — |
| May 28, 2024 | Mar 1, 2024 | -0.08 | -0.08 | 0.00 | 0.00% |
| Apr 3, 2024 | Dec 1, 2023 | 0.00 | -0.07 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 5, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About IceCure Medical Ltd
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Israel
- Website
- icecure-medical.com
News
- IceCure Medical Completes Treatment Of First Patient In Its Post-Marketing Study Evaluating ProSense Cryoablation For Local Treatment Of Low-Risk Breast Cancer
- IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites
- Nexalin Technology (NASDAQ:NXL) vs. IceCure Medical (NASDAQ:ICCM) Financial Analysis
- IceCure Medical Announces Presentations, Posters And Physician Workshops On Its ProSense Breast Cancer Cryoablation At The European Society Of Breast Imaging Annual Scientific Meeting
- IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026
- IceCure Medical Adds Legacy Health In Portland, Oregon, As New U.S. Clinical Site For Its Post-Marketing ChoICE Study Evaluating Prosense Cryoablation For Treatment Of Low-Risk Breast Cancer
- IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site
- IceCure Medical Ltd. (NASDAQ:ICCM) Stock Now Rated “Hold” by Sell-Side Analysts
Your note
Sign in to keep a note on ICCM — it syncs with the Stock Master app.